Vasopressors - Norepinephrine First Line and Choices

Key Points

• Identify the shock mechanism before selecting or escalating vasoactive therapy.
• Norepinephrine is the preferred first-line vasopressor for most adults with septic shock.
• An initial MAP around 65 mm Hg is appropriate for most septic-shock patients, then individualize to perfusion and comorbidity.
• Do not delay urgently needed norepinephrine solely while waiting for central venous access.
• Add vasopressin when norepinephrine requirements escalate and consider epinephrine if MAP remains inadequate.
• A rising vasopressor requirement should trigger reassessment for missed hypovolemia, cardiac dysfunction, obstruction, bleeding, acidosis, or inadequate source control.
• Use inotropes for persistent hypoperfusion from cardiac dysfunction after adequate pressure and volume have been achieved.
• Monitor rhythm, peripheral perfusion, urine output, mental status, lactate trajectory, and access-site safety during therapy.

Algorithm

1. Recognize clinically important hypotension and assess shock phenotype, perfusion, volume responsiveness, and immediately reversible causes.
2. Give appropriate fluid or blood resuscitation and source-specific treatment without delaying vasopressor support in unstable shock.
3. Start norepinephrine and titrate toward an initial MAP near 65 mm Hg while reassessing perfusion.
4. Use a safe peripheral IV initially if central access would delay treatment; monitor the site closely.
5. If norepinephrine needs are escalating, reassess physiology and consider adding vasopressin.
6. If MAP remains inadequate despite norepinephrine and vasopressin, consider epinephrine and obtain advanced hemodynamic assessment.
7. If MAP is adequate but hypoperfusion persists with cardiac dysfunction, consider dobutamine or another appropriate inotropic strategy.
8. Continue serial reassessment and de-escalate vasoactive therapy as the underlying shock resolves.

Clinical Synopsis & Reasoning

Vasopressors are used when arterial pressure is too low to maintain organ perfusion and correction of reversible causes alone is insufficient. The first reasoning step is to identify the shock phenotype. Distributive shock is characterized by pathologic vasodilation and often a relatively preserved or elevated cardiac output early. Cardiogenic shock reflects inadequate forward flow. Hypovolemic and hemorrhagic shock require rapid restoration of circulating volume and source control; vasopressors can be temporarily necessary in profound hypotension but should not substitute for blood or fluid resuscitation. Obstructive shock requires treatment of the obstruction. Bedside examination, lactate trend, urine output, mental status, capillary refill, echocardiography, and response to a passive leg raise or fluid challenge help define the physiology.

Norepinephrine provides potent alpha-1 vasoconstriction with modest beta-1 activity and is the preferred initial vasopressor for most adults with septic shock. It raises systemic vascular resistance and mean arterial pressure with less tachyarrhythmia than dopamine. The 2026 Surviving Sepsis Campaign recommends an initial MAP target near 65 mm Hg for most adults with septic shock, while targets should still be individualized for chronic hypertension, age, neurologic conditions, active bleeding, or evidence of inadequate organ perfusion. A pressure target is therefore a starting point, not the entire endpoint of resuscitation.

Escalating vasopressor requirements should trigger diagnostic reassessment. Persistent hypotension may reflect inadequate preload, occult hemorrhage, severe ventricular dysfunction, tamponade, tension pneumothorax, adrenal insufficiency, uncontrolled infection, profound acidosis, or a medication effect. A rising norepinephrine dose is not by itself proof that more vasoconstrictor is the correct answer. Point-of-care ultrasound and invasive monitoring can be useful when the physiology is unclear, especially when multiple vasoactive agents are required.

Treatment Strategy & Disposition

In septic shock, begin norepinephrine promptly when hypotension persists after initial fluid resuscitation or concurrently with fluids in unstable shock. Current guidance supports starting vasopressors through a well-functioning peripheral IV rather than delaying therapy solely to obtain central access. Use a proximal, visible vein when possible, inspect the site frequently, and transition access according to duration, dose, local protocol, and patient factors. Titrate to the pressure target while repeatedly assessing perfusion rather than chasing an arbitrarily high MAP.

When norepinephrine requirements are escalating, vasopressin can be added as a catecholamine-sparing agent. It acts at V1 receptors and is generally used at a fixed low dose rather than titrated like norepinephrine. If MAP remains inadequate despite norepinephrine and vasopressin, epinephrine is a reasonable additional agent. Epinephrine has strong alpha and beta activity and can increase heart rate, lactate, and myocardial oxygen demand. Dopamine is generally avoided as a routine first-line septic-shock vasopressor because of greater arrhythmia risk, but selected bradyarrhythmic patients may occasionally benefit. Phenylephrine provides nearly pure alpha-1 agonism and can reduce stroke volume; it has niche use when tachyarrhythmia limits other agents or in selected anesthesia settings rather than routine septic shock.

If cardiac dysfunction causes persistent hypoperfusion despite an adequate MAP and volume status, add inotropic support rather than simply escalating vasoconstriction. Dobutamine can increase contractility and cardiac output but may lower blood pressure through vasodilation and provoke tachyarrhythmia. Epinephrine can provide both vasopressor and inotropic effects. Correct severe hypoxemia, acidosis, electrolyte abnormalities, hypocalcemia, temperature derangements, and ongoing blood loss because these can impair cardiovascular response. Refractory shock warrants early critical care expertise and consideration of the underlying cause, corticosteroid strategy when appropriate, mechanical circulatory support in selected cardiogenic cases, and source control.

Epidemiology / Risk Factors

• Vasopressors are most commonly used in distributive and cardiogenic shock and perioperative hypotension.
• Sepsis is a leading cause of vasodilatory shock in hospitalized adults.
• Increasing age, cardiovascular disease, chronic hypertension, and arrhythmia history affect tolerance of both hypotension and catecholamine exposure.
• Shock frequently has mixed physiology, particularly in patients with sepsis and myocardial dysfunction.

Investigations

Profiles

Pharmacology

Prognosis / Complications

• Outcome depends primarily on rapid reversal of the underlying shock cause and restoration of adequate perfusion rather than on any single vasoactive drug.
• Persistent or increasing vasopressor need is a marker of illness severity and should prompt renewed diagnostic evaluation.
• Excessive vasoconstriction can contribute to digital, mesenteric, and other ischemia, especially at high cumulative doses.
• Early recognition of refractory shock and timely escalation to multidisciplinary critical care can improve the opportunity for source control and organ support.

Patient Education / Counseling

• Explain to families that vasopressors support blood pressure while the team treats the underlying cause of shock.
• When a peripheral vasopressor is used, tell awake patients to report burning, pain, swelling, coolness, or color change around the IV site.
• Patients recovering from shock may need follow-up for weakness, kidney injury, cardiac injury, neuropathy, or other post-ICU complications.
• Medication reconciliation after recovery should distinguish temporary ICU vasoactive drugs from chronic antihypertensive or heart-failure therapy.

Notes

Vasopressor choice is inseparable from physiology. Norepinephrine can normalize the MAP of a patient who is still severely underfilled or in cardiogenic shock, but a normal monitor number does not prove that tissue perfusion is adequate. The safest approach pairs drug titration with repeated assessment of the patient, source control, fluid responsiveness, ventricular function, and organ perfusion.

The 2026 Surviving Sepsis Campaign strengthens the practical message that vasopressors should not be delayed for central access and continues to place norepinephrine first in septic shock. It also supports vasopressin as the next common adjunct with escalating norepinephrine and epinephrine when pressure remains inadequate. These recommendations apply to septic shock; hemorrhagic, cardiogenic, obstructive, and neurogenic shock require cause-specific modifications.

References

1. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 — Link